| scholarly article | Q13442814 |
| P2093 | author name string | H Samonigg | |
| A Gerger | |||
| M Pichler | |||
| R Schaberl-Moser | |||
| J Szkandera | |||
| T Stojakovic | |||
| M Stotz | |||
| F Arminger | |||
| G Absenger | |||
| M Weissmueller | |||
| P2860 | cites work | Peripheral lymphocyte and eosinophil counts as indicators of prognosis in primary breast cancer | Q71733129 |
| Prognostic value of tumour-infiltrating lymphocytes (TILs) in colorectal cancer | Q73828602 | ||
| Identification of patients with high-risk stage II colon cancer for adjuvant therapy | Q80826715 | ||
| Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer | Q81105891 | ||
| Population-based study of prognostic factors in stage II colonic cancer | Q83172258 | ||
| Can neutrophil-to-lymphocyte ratio predict the survival of colorectal cancer patients who have received curative surgery electively? | Q83769156 | ||
| Negative impact of neutrophil-lymphocyte ratio on outcome after liver transplantation for hepatocellular carcinoma | Q84136130 | ||
| Elevated preoperative neutrophil to lymphocyte ratio predicts risk of recurrence following curative resection for stage IIA colon cancer | Q84990039 | ||
| Cancer statistics, 2008 | Q27860585 | ||
| Cancer-related inflammation | Q27860907 | ||
| Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging | Q33982101 | ||
| Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? | Q34546887 | ||
| Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer. | Q34806672 | ||
| A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer. | Q36166771 | ||
| Comparison of the prognostic value of selected markers of the systemic inflammatory response in patients with colorectal cancer | Q36611485 | ||
| Validation of the pre-treatment neutrophil-lymphocyte ratio as a prognostic factor in a large European cohort of renal cell carcinoma patients | Q36663605 | ||
| Neutrophil/lymphocyte ratio and its association with survival after complete resection in non-small cell lung cancer | Q37382538 | ||
| The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer | Q38100418 | ||
| Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089. | Q40571922 | ||
| Presence of intratumoral neutrophils is an independent prognostic factor in localized renal cell carcinoma | Q43282875 | ||
| Blood neutrophil-to-lymphocyte ratio predicts survival in patients with colorectal liver metastases treated with systemic chemotherapy. | Q43686080 | ||
| Long-term analysis and prospective validation of a prognostic model for patients with high-risk primary breast cancer receiving high-dose chemotherapy | Q47719805 | ||
| Pretreatment levels of peripheral neutrophils and lymphocytes as independent prognostic factors in patients with nasopharyngeal carcinoma. | Q50967431 | ||
| Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. | Q51597972 | ||
| Gene Expression Signature to Improve Prognosis Prediction of Stage II and III Colorectal Cancer | Q56601042 | ||
| Cancer incidence and mortality in Europe, 2004 | Q56994864 | ||
| Pretreatment neutrophil:lymphocyte ratio as a prognostic factor in cervical carcinoma | Q57225457 | ||
| ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making | Q57758061 | ||
| Prediction of survival using absolute lymphocyte count for newly diagnosed patients with multiple myeloma: a retrospective study | Q60976686 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | patient | Q181600 |
| lymphocyte | Q715347 | ||
| colon cancer | Q18555025 | ||
| P304 | page(s) | 395-400 | |
| P577 | publication date | 2013-07-02 | |
| P1433 | published in | British Journal of Cancer | Q326309 |
| P1476 | title | A derived neutrophil to lymphocyte ratio predicts clinical outcome in stage II and III colon cancer patients | |
| P478 | volume | 109 |
| Q89456485 | Absolute Neutrophil Count Levels among Degree of Differentiation and Tumor Location in Colorectal Cancer Patients in Medan |
| Q37166707 | Activated systemic inflammatory response at diagnosis reduces lymph node count in colonic carcinoma |
| Q55435147 | An inflammation-related nomogram for predicting the survival of patients with non-small cell lung cancer after pulmonary lobectomy. |
| Q51732590 | Analysis of preoperative blood platelet parameters in terms of diversity of epithelial ovarian cancer. |
| Q36027639 | Are neutrophil/lymphocyte ratio and platelet/lymphocyte ratio reliable parameters as prognostic indicators in malignant mesothelioma? |
| Q40853317 | Association of the Derived Neutrophil-Lymphocyte Ratio With Critical Limb Ischemia |
| Q34989484 | Baseline neutrophil-lymphocyte ratio (≥2.8) as a prognostic factor for patients with locally advanced rectal cancer undergoing neoadjuvant chemoradiation |
| Q47238762 | Baseline peripheral blood neutrophil-to-lymphocyte ratio could predict survival in patients with adult polymyositis and dermatomyositis: A retrospective observational study. |
| Q33877471 | C-reactive protein level is a prognostic indicator for survival and improves the predictive ability of the R-IPI score in diffuse large B-cell lymphoma patients. |
| Q48348011 | Colorectal cancer in the young: a possible role for immune surveillance? |
| Q39138898 | Critical evaluation of the potential prognostic value of the pretreatment-derived neutrophil-lymphocyte ratio under consideration of C-reactive protein levels in clear cell renal cell carcinoma |
| Q35743180 | Decreased pretreatment lymphocyte/monocyte ratio is associated with poor prognosis in stage Ib1-IIa cervical cancer patients who undergo radical surgery |
| Q36825610 | Derived neutrophil/lymphocyte ratio predicts gemcitabine therapy outcome in unresectable pancreatic cancer |
| Q35180082 | Differentiation between benign and malignant ovarian masses in the preoperative period using neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios |
| Q33627043 | Do inflammatory markers predict prognosis in patients with synchronous colorectal cancer? |
| Q47615831 | Effects of anaesthesia on proliferation, invasion and apoptosis of LoVo colon cancer cells in vitro. |
| Q58698478 | Elevated amylase in plasma represents an adverse prognostic marker in patients with metastatic pancreatic cancer : A retrospective analysis |
| Q37745835 | Elevated neutrophil-to-lymphocyte ratio and monocyte-to-lymphocyte ratio and decreased platelet-to-lymphocyte ratio are associated with poor prognosis in multiple myeloma |
| Q37588227 | Elevated neutrophil-to-lymphocyte ratio is an independent poor prognostic factor in patients with intrahepatic cholangiocarcinoma |
| Q28542043 | Evaluation of uric acid as a prognostic blood-based marker in a large cohort of pancreatic cancer patients |
| Q35040836 | External validation of the derived neutrophil to lymphocyte ratio as a prognostic marker on a large cohort of pancreatic cancer patients |
| Q57070172 | Increased derived neutrophil-to-lymphocyte ratio and Breast Imaging-Reporting and Data System classification predict poor survival in patients with non-distant metastatic HER2+ breast cancer treated with neoadjuvant chemotherapy |
| Q38366373 | Inflammatory and redox reactions in colorectal carcinogenesis. |
| Q47111810 | Inflammatory biomarkers in metastatic colorectal cancer: prognostic and predictive role beyond the first line setting |
| Q50024652 | Influential factors on radiotherapy efficacy and prognosis in patients with secondary lymph node metastasis after esophagectomy of thoracic esophageal squamous cell carcinoma |
| Q87401437 | Low preoperative lymphocyte-monocyte ratio (LMR) represents a potentially poor prognostic factor in nonmetastatic clear cell renal cell carcinoma |
| Q48278374 | MMC/UFT/LV in refractory colorectal cancer: phase II study and analysis of predictive variables of progression. |
| Q52382940 | Maturation of tertiary lymphoid structures and recurrence of stage II and III colorectal cancer. |
| Q41050161 | Neopterin as a biomarker of immune response in cancer patients |
| Q42814049 | Neutrophil to lymphocyte ratio may be predict of mortality in all conditions |
| Q41002124 | Neutrophil-lymphocyte ratio predicts survival in patients with advanced cholangiocarcinoma on chemotherapy |
| Q38469128 | Neutrophil-to-Lymphocyte Ratio Predicts Early Mortality in Patients with HBV-Related Decompensated Cirrhosis |
| Q92158590 | Neutrophil-to-Lymphocyte Ratio in Ovarian Cancer Patients with Low CA125 Concentration |
| Q41734066 | Neutrophil-to-lymphocyte ratio predicts mortality in patients listed for liver transplantation |
| Q47106977 | Neutrophil-to-lymphocyte ratio predicts survival in European patients with hepatocellular carcinoma administered sorafenib. |
| Q35881343 | Neutrophil/Lymphocyte ratio has no predictive or prognostic value in breast cancer patients undergoing preoperative systemic therapy |
| Q33816141 | Neutrophils in the tumor microenvironment: trying to heal the wound that cannot heal. |
| Q59794859 | Neutrophils to lymphocytes ratio as a useful prognosticator for stage II colorectal cancer patients |
| Q55121878 | Outcomes prediction in pre-operative radiotherapy locally advanced rectal cancer: leucocyte assessment as immune biomarker. |
| Q52884982 | Peripheral Neutrophil to Lymphocyte Ratio Improves Prognostication in Colon Cancer. |
| Q37175931 | Peripheral platelet/lymphocyte ratio predicts lymph node metastasis and acts as a superior prognostic factor for cervical cancer when combined with neutrophil: Lymphocyte |
| Q34987986 | Peritonitis incidence was correlated with duration of peritoneal dialysis rather than leptin or neutrophil to lymphocyte (n/l) ratio in peritoneal dialysis patients |
| Q38146832 | Perspectives in anaesthesia for cancer surgery |
| Q90427580 | Pre-treatment inflammatory biomarkers predict early treatment response and favorable survival in patients with metastatic colorectal cancer who underwent first line cetuximab plus chemotherapy |
| Q37667797 | Preoperative Albumin to Globulin Ratio (AGR) as Prognostic Factor in Renal Cell Carcinoma |
| Q88997602 | Preoperative monocyte-lymphocyte and neutrophil-lymphocyte but not platelet-lymphocyte ratios are predictive of clinical outcomes in resected patients with non-metastatic Siewert type II/III adenocarcinoma of esophagogastric junction: a prospective |
| Q40547023 | Pretreatment hematologic markers as prognostic factors in patients with nasopharyngeal carcinoma: Neutrophil-lymphocyte ratio and platelet-lymphocyte ratio |
| Q35872670 | Prognostic Significance of Preoperative Albumin-Globulin Ratio in Patients with Upper Tract Urothelial Carcinoma |
| Q51482020 | Prognostic Value of the CRP/Alb Ratio, a Novel Inflammation-Based Score in Pancreatic Cancer. |
| Q90322190 | Prognostic Value of the Combined Index of Plasma Fibrinogen and the Neutrophil-Lymphocyte Ratio in Gastric Cancer |
| Q36545358 | Prognostic clinical factors in pretreated colorectal cancer patients receiving regorafenib: implications for clinical management |
| Q41169830 | Prognostic efficacy of inflammation-based markers in patients with curative colorectal cancer resection |
| Q57700802 | Prognostic impact of preoperative lymphocyte-to-monocyte ratio in patients with colorectal cancer with special reference to myeloid-derived suppressor cells |
| Q41162196 | Prognostic performance of inflammation-based prognostic indices in patients with resectable colorectal liver metastases |
| Q58694427 | Prognostic role of derived neutrophil-to-lymphocyte ratio in surgical triple-negative breast cancer |
| Q90102428 | Prognostic role of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in patients with midgut neuroendocrine tumors undergoing resective surgery |
| Q55709763 | Prognostic significance of Ki67 expression and the derived neutrophil-lymphocyte ratio in nasopharyngeal carcinoma. |
| Q33829684 | Prognostic significance of neutrophil-to-lymphocyte ratio in biliary tract cancers: a systematic review and meta-analysis |
| Q37624508 | Prognostic significance of the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in patients with stage III and IV colorectal cancer |
| Q44317521 | Prognostic value of neutrophil-lymphocyte ratio and level of C-reactive protein in a large cohort of pancreatic cancer patients: a retrospective study in a single institute in Japan |
| Q41171241 | Prognostic value of parameters derived from white blood cell and differential counts in patients receiving palliative radiotherapy |
| Q42000248 | Prognostic value of the lymphocyte-to-monocyte ratio and other inflammatory markers in malignant pleural mesothelioma |
| Q42814037 | Reply: comment on 'A derived neutrophil to lymphocyte ratio predicts clinical outcome in stage II and III colon cancer patients'. |
| Q35651537 | Significance of the preoperative neutrophil-to-lymphocyte ratio in the prognosis of patients with gastric cancer |
| Q52605888 | The Predictive Value of Inflammation-Related Peripheral Blood Measurements in Cancer Staging and Prognosis. |
| Q64978863 | The accuracy of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio as a marker for gastrointestinal malignancies. |
| Q40235024 | The clinical significance of fibrinogen plasma levels in patients with diffuse large B cell lymphoma. |
| Q37507473 | The derived neutrophil to lymphocyte ratio is an independent prognostic factor in patients with diffuse large B-cell lymphoma |
| Q55413490 | The dynamic change of neutrophil to lymphocyte ratio can predict clinical outcome in stage I-III colon cancer. |
| Q33613591 | The elevated preoperative platelet-to-lymphocyte ratio predicts poor prognosis in breast cancer patients |
| Q37507488 | The preoperative lymphocyte to monocyte ratio predicts clinical outcome in patients with stage III colon cancer |
| Q42674196 | The prognostic value of derived neutrophil to lymphocyte ratio in oesophageal cancer treated with definitive chemoradiotherapy |
| Q47098424 | The prognostic value of neutrophil to lymphocyte and platelet to lymphocyte ratios for patients with lung cancer |
| Q41996520 | The prognostic value of neutrophil-lymphocyte ratio is superior to derived neutrophil-lymphocyte ratio in advanced gastric cancer treated with preoperative chemotherapy and sequential R0 resection: a 5-year follow-up |
| Q53228738 | The prognostic value of preoperative NLR, d-NLR, PLR and LMR for predicting clinical outcome in surgical colorectal cancer patients. |
| Q36638119 | The role of neutrophil lymphocyte ratio to leverage the differential diagnosis of familial Mediterranean fever attack and acute appendicitis |
| Q47338550 | The role of the systemic inflammatory response in predicting outcomes in patients with operable cancer: Systematic review and meta-analysis. |
| Q38235867 | The tumour-induced systemic environment as a critical regulator of cancer progression and metastasis |
| Q36334640 | Timing of chemotherapy-induced neutropenia predicts prognosis in metastatic colon cancer patients: a retrospective study in mFOLFOX6 -treated patients |
| Q37459643 | Validation of C-reactive protein levels as a prognostic indicator for survival in a large cohort of pancreatic cancer patients. |
| Q33613637 | Validation of the pretreatment derived neutrophil-lymphocyte ratio as a prognostic factor in a European cohort of patients with upper tract urothelial carcinoma |
| Q37279275 | Validation of the prognostic relevance of plasma C-reactive protein levels in soft-tissue sarcoma patients |
Search more.